Join our daily newsletter At The Bell to receive exclusive market insights
- Palla Pharma (PAL) has formally launched its Co-Codamol 30/500 caplet in the U.K. market
- The Australian opiate manufacturer supplies the global pain relief market
- PAL’s Co-Codamol caplet is the first of its products to be launched after it received final approval from the U.K.’s Medicines and Healthcare Products Regulatory Agency (MHRA) in late February
- Meanwhile, PAL has entered into a partnership agreement with M&A Pharmachem
- The deal secures Palla Pharma access to manufacturing capacity at M&A’s U.K. facility, thereby enhancing its ability to reliably supply the U.K. market
- Palla Pharma shares have dipped 4.44 per cent to trade at 43 cents each
Palla Pharma (PAL) has formally launched its Co-Codamol 30/500 caplet in the U.K. market.
The Australian opiate manufacturer supplies the global pain relief market.
Its Co-Codamol product is the first the be launched by the company after receiving final approval of its marketing authorisation from the U.K.’s Medicines and Healthcare Products Regulatory Agency (MHRA) in late February.
Palla says further products will follow over the coming months with a co-dydramol finished dose formulation expected for launch in the third quarter.
Partnership with M&A Pharmachem
Meanwhile, the company has settled all outstanding legal issues with its largest application programming interface (API) customer M&A Pharmachem to enter into a long-term production partnership.
The deal covers marketing authorisation licences, contract manufacturing and API supply agreements, which together secure Palla Pharma access to manufacturing capacity at M&A’s U.K. facility.
Importantly, PAL says the partnership enhances its ability to reliably supply the U.K. market with significant product volumes from separate manufacturing sites.
Palla Pharma expects to access the products manufactured through the partnership in the third quarter.
As the company eyes European market entry, approval processes for the PAL’s five other marketing authorisations are ongoing.
Late in the session, Palla Pharma shares have dipped 4.44 per cent to trade at 43 cents at 4:55 pm AEST.
